

# The 14th consensus document from the European Bifurcation Club

Yves Iouvard, ICPS Massy, Générale de Santé –  
Ramsay, France



**No conflict of interest to declare**



**CORONARY INTERVENTIONS**

# Percutaneous coronary intervention for obstructive bifurcation lesions: the 14th consensus document from the European Bifurcation Club

EuroIntervention 2019;15:90-98. DOI: 10.4244/EIJ-D-19-00144



Adrian P. Banning<sup>1</sup>, MD; Jens Flensted Lassen<sup>2</sup>, MD; Francesco Burzotta<sup>3</sup>, MD, PhD; Thierry Lefèvre<sup>4</sup>, MD; Olivier Darremont<sup>5</sup>, MD; David Hildick-Smith<sup>6</sup>, MD; Yves Louvard<sup>4</sup>, MD; Goran Stankovic<sup>7</sup>, MD, PhD; on behalf of the European Bifurcation Club

1. Department of Cardiology, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford University Hospitals, Oxford, United Kingdom; 2. Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen Copenhagen, Denmark; 3. Institute of Cardiology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 4. Ramsay Générale de Santé - Institut Cardiovasculaire Paris Sud, Hopital Privé Jacques Cartier, Massy, France; 5. Clinique St Augustin, Bordeaux, France; 6. Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 7. Department of Cardiology, Clinical Center of Serbia, and Faculty of Medicine, University of Belgrade, Belgrade, Serbia

**Abstract**

The European Bifurcation Club recommends an approach to a bifurcation stenosis which involves careful assessment, planning and a sequential provisional approach. In the minority of lesions where two stents are required, careful deployment and optimal expansion are essential to achieve a long-term result.



**RELATED ISSUE**

**Volume 15 Number 1**

→ VIEW CONTENTS

**TOOLBOX**

- ▶ Print article
- ▶ Citations
- ▶ Ask for a reprint
- ▶ Request permissions

**METRICS**

Dimensions Badge

## EBC glossary

## How to define a bifurcation lesion ?

- A coronary artery narrowing occurring adjacent to, and/or involving, the origin of a significant side branch
- A significant SB is a branch that you don't want to lose in the global context of a particular patient

# Medina Classification














Figure 1

# How to name a bifurcation lesion ?



# Bifurcation angles



A= Access  
B= Between



## Classification of Coronary Artery Bifurcation Lesions and Treatments: Time for a Consensus!

Yves Louvard,<sup>1\*</sup> MD, Martyn Thomas,<sup>2</sup> MD, Vladimir Dzavik,<sup>3</sup> MD, David Hildick-Smith,<sup>4</sup> MD, Alfredo R. Galassi,<sup>5</sup> MD, Manuel Pan,<sup>6</sup> MD, Francisco Burzotta,<sup>7</sup> MD, Michael Zelizko,<sup>8</sup> MD, Darius Dudek,<sup>9</sup> MD, Peter Ludman,<sup>10</sup> MD, Imad Sheiban,<sup>11</sup> MD, Jens F. Lassen,<sup>12</sup> MD, Olivier Darremont,<sup>13</sup> MD, Adnan Kastrati,<sup>14</sup> MD, Josef Ludwig,<sup>15</sup> MD, Ioannis Iakovou,<sup>16</sup> MD, Philippe Brunel,<sup>17</sup> MD, Alexandra Lansky,<sup>18</sup> MD, David Meerkink,<sup>19</sup> MD, Victor Legrand,<sup>20</sup> MD, Alfonso Medina,<sup>21</sup> MD, and Thierry Lefèvre,<sup>1</sup> MD

**Background:** Percutaneous coronary intervention (PCI) of coronary bifurcation lesions remains a subject of debate. Many studies have been published in this setting. They are often small scale and display methodological flaws and other shortcomings such as inaccurate designation of lesions, heterogeneity, and inadequate description of techniques implemented. **Methods:** The aim is to propose a consensus established by the European Bifurcation Club (EBC), on the definition and classification of bifurcation lesions and treatments implemented with the purpose of allowing comparisons between techniques in various anatomical and clinical settings. **Results:** A bifurcation lesion is a coronary artery narrowing occurring adjacent to, and/or involving, the origin of a significant side branch. The simple lesion classification proposed by Medina has been adopted. To analyze the outcomes of different techniques by intention to treat, it is necessary to clearly define which vessel is the distal main branch and which is (are) the side branch(es) and give each branch a distinct name. Each segment of the bifurcation has been named following the same pattern as the Medina classification. The classification of the techniques (MADS: Main, Across, Distal, Side) is based on the manner in which the first stent has been implanted. A visual presentation of PCI techniques and devices used should allow the development of a software describing quickly and accurately the procedure performed. **Conclusion:** The EBC proposes a new classification of bifurcation lesions and their treatments to permit accurate comparisons of well described techniques in homogeneous lesion groups. © 2008 Wiley-Liss, Inc.

**Key words:** bifurcation lesions; QCA; classification of bifurcation lesions; classification of treatments

# Quantitative angiography methods for bifurcation lesions: a consensus statement update from the European Bifurcation Club



Carlos Collet<sup>1</sup>, MD; Yoshinobu Onuma<sup>2</sup>, MD, PhD; Rafael Cavalcante<sup>3</sup>, MD, PhD; Maik Grundeken<sup>1</sup>, MD, PhD; Philippe Généreux<sup>4,5,6,7</sup>, MD; Jeffrey Popma<sup>8</sup>, MD; Ricardo Costa<sup>9</sup>, MD, PhD; Goran Stankovic<sup>10</sup>, MD; Shengxian Tu<sup>11</sup>, MD, PhD; Johan H.C. Reiber<sup>12</sup>, PhD; Jean-Paul Aben<sup>13</sup>, PhD; Jens Flensted Lassen<sup>14</sup>, MD, PhD; Yves Louvard<sup>15</sup>, MD; Alexandra Lansky<sup>16</sup>, MD; Patrick W. Serruys<sup>17\*</sup>, MD, PhD

This document is endorsed by the EAPCI.

EAPCI Scientific Documents Committee: Robert A. Byrne<sup>18</sup>, MB, BCh, PhD; Davide Capodanno<sup>19</sup>, MD

EAPCI review co-ordinator: Ron Waksman<sup>20</sup>, MD

Document reviewers: Hector-M. Garcia-Garcia<sup>20</sup>, MD, PhD; Armin Arbab-Zadeh<sup>21</sup>, MD

*1. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Cardialysis BV, Rotterdam, the Netherlands; 3. Erasmus Medical Center, Rotterdam, the Netherlands; 4. Cardiovascular Research Foundation, New York.*


# New MADS

	<b>M</b> Main prox. first	<b>A</b> Main Across side first (Provisional)	<b>D</b> Double prox. lumen	<b>S</b> Side branch first
<b>1<sup>st</sup> stent</b>	 PM stenting	 MB cross-over stenting		 SB ostial stenting
<b>Ballooning</b>	 Skirt (K)	 POT Side-branch dilation Kissing <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             S PS PK PSP PKP           </div>		 Balloon SB crush <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             S K           </div>
<b>2<sup>nd</sup>-3<sup>rd</sup> stent, (and further ballooning)</b>	 Extended skirt (K)	 T TAP Culotte <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             K KP           </div>	 V / SKS	 Intentional T stenting <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             PK PKP           </div> Step/DK crush
<b>Dedicated Device:</b>	Axxess	Bioss LIM, Xposition Stentys, Nile SIR		Capella Side-Guard



**Use of a provisional SB stenting strategy is one of the fundamental philosophies of the EBC**

# Long-term risk of clinical events from stenting SB of coronary bifurcation lesions with DES / BMS: meta-analysis





6825 subjects  
from 42 studies

# Korean Bifurcation Pooled Cohorts

## Impact of 2<sup>nd</sup> generation DES

- 2,897 patients from COBIS II, 265 patients from EXCELLENT registry and RESOLUTE-Korea registry




**In this era of 2<sup>nd</sup> generation DES, 2-stent technique is safe.**

# Late Thrombosis After 2 Versus 1 DES in the Treatment of Coronary Bifurcations. Meta-analysis of Randomized and Observational Studies


**A**

DES Thrombosis







# Late Thrombosis After 2 Versus 1 DES in the Treatment of Coronary Bifurcations. Meta-analysis of Randomized and Observational Studies



# Nordic and BBC1 study long-term outcome (death)



from Miles Behan



from Terje Steigen EBC 2017


# Randomized study comparing Double Kissing Crush with Provisional Stenting for treatment of coronary bifurcation lesions: DK-CRUSH-II

## Clinical outcome (2)

	DK Group (n = 185)	PS Group (n = 185)	p Value
<b>Procedural success</b>	<b>179 (96.8)</b>	<b>173 (93.5)</b>	<b>0.217</b>
<b>At 6-month</b>			
Cardiac death	1 (0.5)	2 (1.1)	1.000
MI	6 (3.2)	4 (2.2)	0.751
CABG	0 (0)	1 (0.5)	0.500
TLR	2 (1.1)	6 (3.2)	0.284
TVR	3 (1.6)	8 (4.3)	0.220
MACE	6 (3.2)	11 (5.9)	0.321
Stent thrombosis definite	4 (2.2)	1 (0.5)	0.372
<b>At 12-month</b>			
Cardiac death	2 (1.1)	2 (1.1)	1.000
MI	6 (3.2)	4 (2.2)	0.751
CABG	0 (0)	1 (0.5)	0.500
TLR	8 (4.3)	24 (13.0)	0.005
TVR	12 (6.5)	27 (14.6)	0.017
MACE	19 (10.3)	32 (17.3)	0.070
Stent thrombosis	5 (2.7)	2 (1.1)	0.449
Definite	4 (2.2)	1 (0.5)	0.372
Possible	1 (0.5)	1 (0.5)	1.000

## Follow-up coronary angiography at 8 months

# Two-year MACE




Number at risk		0	100	200	300	400	500	600	700
Two-stent tech.	228	221	221	214	212	211	209	206	
Provisional tech.	218	209	208	196	194	192	189	187	

**MACE:** cardiac death, non-procedural myocardial infarction, target lesion revascularization and definite stent thrombosis

# The EBC TWO study: randomized comparison of Provisional T-Stenting vs a systematic 2 stent Culotte strategy in large caliber true bifurcations


All-cause death, MI, and TVR



## Assessing the importance of the SB

## Which side branch deserves stent implantation?

- In terms of ischemia at risk, revascularization is better than medical treatment when moderate to severe ischemia exists. Therefore, it is important **to define the side branches that can cause  $\geq 10\%$  ischemia**




## 2014 ESC/EACTS Guidelines on myocardial revascularization

Extent of CAD (anatomical and/or functional)		Class <sup>b</sup>	Level <sup>c</sup>	References
<b>For prognosis</b>	Left main disease with stenosis >50% <sup>a</sup>	I	A	108,134,135
	Any proximal LAD stenosis >50% <sup>a</sup>	I	A	94,108,135,136
	Two-vessel or three-vessel disease with stenosis > 50% <sup>a</sup> with impaired LV function (LVEF<40%) <sup>a</sup>	I	A	93,94,108,112,121,135,137–142
	Large area of ischaemia (>10% LV)	I	B	54,91,97,99,143,144
	Single remaining patent coronary artery with stenosis >50% <sup>a</sup>	I	C	
<b>For symptoms</b>	Any coronary stenosis >50% <sup>a</sup> in the presence of limiting angina or angina equivalent, unresponsive to medical therapy	I	A	54,96,105,108,118–120,145



# Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging


## Definitions of Moderate-Severe Ischemia



Comparable multimodality estimates of moderate-severe ischemia using risk-based thresholds of CAD death or MI rates of 4% to 6%/year

# Relation of angiographic SB calibre to myocardial mass: a proof of concept myocardial infarct index





A schematic of the relation between SB lumen CSA and perfused myocardial mass



Myocardial Mass At Risk (MMAR)  
or Fractional Myocardial Mass (FMM)

Myocardial ischemia

# Structure-function scaling laws of vascular trees



\* 2.3 (Huo-Kassab)

Adapted from G. Kassab



# Identification of Coronary Artery Side Branch Supplying Myocardial Mass That May Benefit From Revascularization

## Multivariate Generalized Estimating Equations Modeling for Prediction of %FMM >10%

	Odds Ratio ± SE	p Value
Side branch length ≥73 mm	41.9 ± 2.1	<0.001
Left main bifurcation	345.2 ± 2.9	<0.001
Reference vessel diameter ≥2.68 mm	1.5 ± 1.9	0.73
Left ventricular mass >104.8 g	1.4 ± 1.8	0.61
Fractional flow reserve <0.80	2.3 ± 2.2	0.24

Multivariate generalized estimating equations modeling was performed using optimal cutoffs of each parameters predicting FMM >10%. The respective c-statistics of left main bifurcation, reference vessel diameter >2.68 mm, left ventricular mass >104.8 g, and FFR <0.80 were 0.820, 0.734, 0.609, and 0.526 (p < 0.05, all)

# Myocardial segmentation techniques with CT scan





## Fractional Myocardial Mass (FFM)

- Myocardial mass supplied by a specific vessel
- **Calculated from vessel length in CT**
- FMM was computed using stem and crown model based on allometric system

HY Kim, JACC Cardiovasc Interv 2017


## Myocardial mass at risk (MMAR)



Sumitsuji, Cardiovasc Interv and Ther 2015

# Identification of coronary artery SB supplying myocardial mass that may benefit from revascularization

Frequency of side branch supplying %FMM  $\geq 10\%$




**Only 1 out of every 5 non-LM SB supplies %FMM  $\geq 10\%$**

## Modified SNUH score (Diagonal branches)

Variables	Description	Score
Size	Vessel diameter $\geq 2.5\text{mm}$	1
	Number of diagonal branches = 1	2
Number	Number of diagonal branches = 2	1
	Number of diagonal branches $\geq 3$	0
Ubiety	Left dominant or Apical area reaching OM branch	-1*
Highest	No branch below the target branch in proximal to mid LAD	1

\*If total score is 0, then -1 is not added (The lowest total score is 0)

## Do we have a new coronary bifurcation stenosis definition ?





## Provisional stenting strategy step by step

# Predictors and Outcomes of SB Occlusion After Main Vessel Stenting in Coronary Bifurcation Lesions Results From the COBIS II Registry

## Lesion and Procedural Characteristics



Characteristic	SB Occlusion (n = 187)	No SB Occlusion (n = 2,040)	p Value
<b>Bifurcation location</b>			<b>&lt;0.001</b>
Left main bifurcation	14 (7.5)	556 (27.3)	
LAD/diagonal	124 (66.3)	1,124 (55.1)	
LCX/OM	32 (17.1)	272 (13.3)	
RCA bifurcation	17 (9.1)	88 (4.3)	
<b>Medina classification</b>			<b>&lt;0.001</b>
1.1.1	97 (51.9)	567 (27.8)	
1.0.1	21 (11.2)	136 (6.7)	
0.1.1	21 (11.2)	198 (9.7)	
1.0.0	19 (10.2)	297 (14.6)	
1.1.0	25 (13.4)	355 (17.4)	
0.1.0	4 (2.1)	462 (22.6)	

**Patients with recovery of the occluded SB had jailed wire in the SB more frequently than those without recovery of the occluded SB (74.8% vs. 57.8%, p < 0.02)**

**SB occlusion  
wo JW = 7%  
w JW = 9%**


Zotarolimus-eluting stent	23 (12.3)	234 (11.5)	
Everolimus-eluting stent	26 (13.9)	246 (12.1)	
Other drug-eluting stents	6 (3.2)	49 (2.4)	
<b>Jailed wire in the SB</b>	<b>123 (65.8)</b>	<b>1,237 (60.6)</b>	<b>0.17</b>
SB pre-dilation before MV stenting	61 (32.6)	437 (21.4)	<0.001
Guidance of intravascular ultrasound	52 (27.8)	772 (37.8)	0.007
MV stent diameter, mm (range)	3.0 (3.0–3.5)	3.0 (3.0–3.5)	0.04
MV stent length, mm (range)	24.0 (20.0–30.0)	24.0 (18.0–30.0)	0.21
MV stent maximal pressure, atm (range)	12.0 (10.0–14.0)	14.0 (10.0–16.0)	<0.001
MV stent/artery ratio (range)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	0.63

# Assessment of side branch predilation before a provisional T-stent strategy for bifurcation lesions. A randomized trial




# EBC 2012: stimulation era

## Provisional stenting strategy



# Stent diameter



**Optimal  
Provisional SB  
Stenting**


**POT**

## Independant predictors of SB occlusion


Variable	Odds Ratio (95% CI) (range)	p Value
Pre-procedural %DS of the SB $\geq$ 50%	2.34 (1.59-3.43)	<0.001
Pre-procedural %DS of the proximal MV $\geq$ 50%	2.34 (1.57-3.50)	0.03
SB lesion length	1.03 (1.003-1.06)	<0.001
Acute coronary syndrome	1.53 (1.06-2.19)	0.02
Left main lesions (vs. non-left main lesions)	0.34 (0.16-0.72)	0.005

# IVUS findings of Carina shift vs. Plaque shift

carina shift



Both plaque shift and carina shift → Aggravation of SB luminal narrowing after MB stent implantation




## COBIS II POT Study: Clinical outcomes

- Patients with **SB diameter**  $\geq 2.5$  mm in core-lab QCA (N=1,191)
- Propensity score-matching population

	<b>POT</b> (n=204)	<b>No POT</b> (n=665)	<b>HR (95% CI)</b>	<b>p value</b>
<b>MACE</b>	<b>6 (2.9)</b>	<b>78 (11.7)</b>	<b>0.25 (0.11-0.60)</b>	<b>0.002</b>
<b>All-cause death</b>	7 (3.4)	25 (3.8)	0.97 (0.41-2.33)	0.95
<b>Cardiac death</b>	1 (0.5)	9 (1.4)	0.37 (0.05-2.97)	0.35
<b>Myocardial infarction</b>	0	12 (1.8)	-	-
<b>Stent thrombosis</b>	2 (1.0)	8 (1.2)	0.98 (0.20-4.77)	0.98
<b>TLR</b>	5 (2.5)	61 (9.2)	0.27 (0.10-0.69)	<b>0.006</b>
<b>MV, proximal</b>	<b>3 (1.5)</b>	<b>40 (6.0)</b>	<b>0.25 (0.07-0.82)</b>	<b>0.02</b>
<b>MV, distal</b>	<b>4 (2.0)</b>	<b>47 (7.1)</b>	<b>0.28 (0.10-0.80)</b>	<b>0.02</b>
<b>SB</b>	4 (2.0)	35 (5.3)	0.37 (0.13-1.09)	0.07
<b>Both vessels</b>	5 (2.5)	48 (7.2)	0.34 (0.13-0.88)	<b>0.03</b>



## Proximal vs distal recrossing toward side branch



# COBIS II

## FKB during 1-stent techniques


- Treated with 1-stent techniques: N=1,901
- Final kissing ballooning (FKB): N=620
- Propensity score-matched analysis: N=545 pairs

Clinical data	Adjusted HR (95% CI)	p Value	QCA data (mm)	FKB	Non-FKB	p Value
<b>MACE</b>	<b>0.50 (0.30-0.85)</b>	<b>0.01</b>	Main vessel			
Cardiac death	0.50 (0.11-2.29)	0.37	Proximal MLD	3.27	3.04	<0.001
MI	0.18 (0.01-20.4)	0.48	Middle MLD	2.86	2.72	<0.001
Stent thrombosis, definite or probable	0.77 (0.17-3.45)	0.73	Distal MLD	2.83	2.73	0.04
<b>TLR</b>	<b>0.51 (0.28-0.91)</b>	<b>0.02</b>	Side branch			
<b>Main vessel</b>	<b>0.51 (0.28-0.93)</b>	<b>0.03</b>	Ostial MLD	1.85	1.36	<0.001
Side branch	0.57 (0.24-1.37)	0.21	Distal MLD	2.15	1.99	0.04

**When you stent a bifurcation lesion with a large SB, FKB will achieve a better MV stent expansion, which will reduce the risk of TLR.**



# Significant Post Stenting SB Stenosis: QCA vs FFR

(jailed side branch lesions, n=94)




# POT-Side-POT as an alternative to FKBI?

POT-Side-POT is better in the bench test





### Nordic-Baltic III, 5yr cardiac death




Number at risk

	0	300	600	900	1200	1500	1800
FKBD	235	220	212	206	196	189	184
no-FKBD	237	222	214	211	207	201	197


# SB stenting

	<b>M</b> Main prox. first	<b>A</b> Main Across side first (Provisional)	<b>D</b> Double prox. lumen	<b>S</b> Side branch first
<b>1<sup>st</sup> stent</b>	 PM stenting	 MB cross-over stenting		 SB ostial stenting
<b>Ballooning</b>	 Skirt (K)	 POT Side-branch dilation Kissing <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             S PS PK PSP PKP           </div>		 Balloon SB crush <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             S K           </div>
<b>2<sup>nd</sup>-3<sup>rd</sup> stent, (and further ballooning)</b>	 Extended skirt (K)	 T TAP Culotte <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             K KP           </div>	 V / SKS	 Intentional T stenting <div style="border: 1px solid black; padding: 2px; display: inline-block; margin-left: 10px;">             PK PKP           </div> Step/DK crush
<b>Dedicated Device:</b>	Axxess	Bioss LIM, Xposition Stentys, Nile SIR		Capella Side-Guard

## T or TAP stenting ?



↓  
T




↓  
TAP

**EBC recommendations on elective use of two stent techniques in bifurcations.**



# Nordic bifurcation II




**DKCRUSH-III**

## Clinical follow-up (at 12-month)


	<b>DK crush (n=210)</b>	<b>Culotte (n=209)</b>	<b>p</b>
<b>Composite MACE, n(%)</b>	<b>13(6.2)</b>	<b>34(16.3)</b>	<b>0.001</b>
Cardiac death	2(1.0)	2(1.0)	1.000
MI	7(3.3)	11(5.3)	0.377
TLR	<b>5(2.4)</b>	<b>14(6.7)</b>	<b>0.037</b>
TVR	<b>9(4.3)</b>	<b>23(11.0)</b>	<b>0.016</b>
For non-left main	0	4(1.9)	0.061
For left main	9(4.3)	20(9.6)	0.036
CABG	2(1.0)	0	0.499
<b>Stent thrombosis, n(%)</b>	<b>1(0.5)</b>	<b>2(1.0)</b>	<b>0.623</b>
Definite	0	2(1.0)	0.248
Probable	0	0	NS
Possible	1(0.5)	0	1.000

## Clinical outcome at 1 year



# Randomized Comparison of the Crush Versus the Culotte Stenting for Coronary Artery Bifurcation Lesions

Major adverse cardiac event-free survival rate at 12 months



Original Colombo  
crush

Original Chevalier  
culotte (main first)

# Intracoronary imaging

## Joint consensus on the use of OCT in coronary bifurcation lesions by the European and Japanese bifurcation clubs



**Yoshinobu Onuma**<sup>1</sup>, MD, PhD; Yuki Katagiri<sup>2</sup>, MD; Francesco Burzotta<sup>3</sup>, MD; Niels Ramsing Holm<sup>4</sup>, MD; Nicolas Amabile<sup>5</sup>, MD, PhD; Takayuki Okamura<sup>6</sup>, MD, PhD; Gary S. Mintz<sup>7</sup>, MD; Olivier Darremont<sup>8</sup>, MD; Jens Flensted Lassen<sup>9</sup>, MD, PhD; Thierry Lefèvre<sup>10</sup>, MD; Yves Louvard<sup>10</sup>, MD; Goran Stankovic<sup>11</sup>, MD, PhD; Patrick W. Serruys<sup>12\*</sup>, MD, PhD

*1. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 2. Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; 3. Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy; 4. Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark; 5. Cardiology Department, Institut Mutualiste Montsouris, Paris, France; 6. Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan; 7. Cardiovascular Research Foundation, New York, NY, USA; 8. Clinique St. Augustin, Bordeaux, France; 9. Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 10. Ramsay Générale de Santé - Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France; 11. Department of Cardiology, Clinical Center of Serbia, and Medical Faculty, University of Belgrade, Belgrade, Serbia; 12. International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom*

## Intravascular ultrasound in the evaluation and treatment of left main coronary artery disease: a consensus statement from the European Bifurcation Club



**Gary S. Mintz**<sup>1</sup>, MD; Thierry Lefevre<sup>2</sup>, MD; Jens F. Lassen<sup>3</sup>, MD; Luca Testa<sup>4</sup>, MD; Manuel Pan<sup>5</sup>, MD; Jag Singh<sup>6</sup>, MD; Goran Stankovic<sup>7</sup>, MD; Adrian P. Banning<sup>8\*</sup>, MD

*1. Cardiovascular Research Foundation, New York, NY, USA; 2. Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France; 3. Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 4. Department of Cardiology, IRCCS Policlinico S. Donato, San Donato Milanese, Milan, Italy; 5. Department of Cardiology, Reina Sofia Hospital, University of Cordoba (IMBIC), Cordoba, Spain; 6. Division of Cardiology, Department of*

## The Left Main

## Percutaneous coronary intervention in left main coronary artery disease: the 13<sup>th</sup> consensus document from the European Bifurcation Club



Francesco Burzotta<sup>1\*</sup>, MD, PhD; Jens Flensted Lassen<sup>2</sup>, MD, PhD; Adrian P. Banning<sup>3</sup>, MD, PhD; Thierry Lefèvre<sup>4</sup>, MD; David Hildick-Smith<sup>5</sup>, MD; Alaide Chieffo<sup>6</sup>, MD; Olivier Darremont<sup>7</sup>, MD; Manuel Pan<sup>8</sup>, MD; Yiannis S. Chatzizisis<sup>9</sup>, MD, PhD; Remo Albiero<sup>10</sup>, MD; Yves Louvard<sup>4</sup>, MD; Goran Stankovic<sup>11</sup>, MD, PhD

*1. Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy; 2. Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 3. Cardiovascular Medicine Division, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom; 4. Ramsay Générale de Santé - Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques Cartier, Massy, France; 5. Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 6. Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; 7. Clinique St Augustin, Bordeaux, France; 8. Department of Cardiology, Reina Sofia Hospital, University of Cordoba (IMIBIC), Cordoba, Spain; 9. Cardiovascular Division, University of Nebraska Medical Center, Omaha, NE, USA; 10. Instituto Clinico San Rocco, Ome (Brescia), Italy; 11. Department of Cardiology, Clinical Center of Serbia, and Medical Faculty, University of Belgrade, Belgrade, Serbia*

*The complete list of references is published online at: [http://www.pcronline.com/eurointervention/134th\\_issue/16](http://www.pcronline.com/eurointervention/134th_issue/16)*




# COBIS II

## 1-stent vs. 2-stent in left main bifurcation


PS-matched population

**Cardiac death or MI**



No. at risk	0	365	730	1095
1-stent	192	169	136	79
2-stent	192	164	127	73

**Target Lesion Revascularization**



No. at risk	0	365	730	1095
1-stent	192	165	129	77
2-stent	192	149	109	66

**The conservative provisional approach is still the standard strategy to treat left main bifurcation.**

## DK Crush V conclusion

In the present multicenter randomized trial, a planned DK crush 2-stent strategy reduced TLF at 1-year compared with a PS strategy in patients with **true distal LM bifurcation lesions**


Chen SL, J Am Coll Cardiol 2017;70:2605–17

## ESC-EACTS 2018 recommendations

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Stent implantation in the main vessel only, followed by provisional balloon angioplasty with or without stenting of the side branch, is recommended for PCI of bifurcation lesions. <sup>654–658</sup>	<b>I</b>	<b>A</b>
Percutaneous revascularization of CTOs should be considered in patients with angina resistant to medical therapy or with a large area of documented ischaemia in the territory of the occluded vessel. <sup>629,659–663</sup>	<b>IIa</b>	<b>B</b>
In true bifurcation lesions of the left main, the double-kissing crush technique may be preferred over provisional T-stenting. <sup>620</sup>	<b>IIb</b>	<b>B</b>

# DKCrush vs Provisional stenting for LM distal bifurcation lesions (1,1,1-0,1,1): DKCRUSH-V randomized trial

D




No. at risk						
DK crush	240	240	240	236	231	224
Provisional stenting	242	238	237	236	234	218

Angiographic FU in 65.3% and 66.3% at 367±49 days and 371 ± 52 days, in PS and DK-Crush respectively


# Treatment in DK Crush V

A


Target Lesion Failure



No. at risk	0	1	3	6	9	12
DK crush	240	239	239	236	230	224
Provisional stenting	242	236	235	234	231	216





# Death, MI, Stroke or IDR Through 3 Years



# DES Designs Overexpansion

Balloon  
Max  
Size




		Synergy	Xpedition	Res. Onyx	Ultimaster	BioMatrix A	Orsiro
4.0	2.25	Small vessel (8 crowns, 2-4 connectors) <i>Expansion: 3.6mm</i>	Small vessel (6 crowns, 3 connectors) <i>Expansion: 4.1mm</i>	Small vessel workhorse (6.5 crowns, 2 connectors) <i>Expansion: 3.3mm</i>	Small vessel (8 crowns, 2 connectors) <i>Expansion: 4.3mm</i>	Small vessel (6 crowns, 2 connectors) <i>Expansion: 4.1mm</i>	Small vessel (6 crowns, 3 connectors) <i>Expansion: 4.0mm</i>
	2.50						
5.0	2.75			Medium vessel workhorse (8.5 crowns, 2 connectors) <i>Expansion: 4.4mm</i>			
	3.00	Workhorse (8 crowns, 2-4 connectors) <i>Expansion: 4.2mm</i>					
	3.50		Large vessel (9 crowns, 3 connectors) <i>Expansion: 5.6mm</i>	Large vessel (9.5 crowns, 2.5 connectors) <i>Expansion: 5.6mm</i>	Large vessel (8 crowns, 2 connectors) <i>Expansion: 5.8mm</i>	Large vessel (9 crowns, 3 connectors) <i>Expansion: 5.9mm</i>	Large vessel (6 crowns, 3 connectors) <i>Expansion: 5.3mm</i>
6.0	4.00	Large vessel (10 crowns, 2-5 connectors) <i>Exp: 5.7mm</i>					
	4.50			Extra-Large vessel (10.5 crowns, 2.5 connectors) <i>Expansion: 6.0mm</i>			
	5.00						

- *Expansion : inner stent MLD excluding struts*
- *Max balloon size : Maverick 6.0mm at 14 ATM*

Foin, Ng, 2016

# Impact of operator experience and volume on outcomes after LMCA PCI

## Outcomes at 30 Days



At least 15 LM PCIs per year for at least 3 consecutive years